Gene therapy pricing models

The expanding landscape for cell and gene therapies (CGT) promises to transform treatment for oncology, rare diseases, and other diseases. However, due to the high cost of cell and gene therapies, financial innovation may be necessary to help drive the availability and accessibility of these therapies. Here, we suggest three cell and gene therapy pricing models that could change the way CGT are financed.

Transformative therapies require innovative payment models

The cell and gene therapy landscape continues to change at an unprecedented pace—14 CGTs are in the US market today, and an estimated 30–40 manufacturers have CGTs in their near-term pipelines. Some estimates suggest that approximately 100,000...